Hepion Pharmaceuticals, Inc.

HEPA | OTC | CIK: 0001583771 | SIC: 2834 Pharmaceutical Preparations | active
Morristown, New Jersey
Hepion Pharmaceuticals, Inc. is a medical diagnostic company headquartered in Morristown, New Jersey. Previously focused on chronic liver disease drug therapy via its cyclophilin inhibitor rencofilstat, the company pivoted to diagnostics after halting its ASCEND-NASH clinical trial. It in-licensed diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B/RSV), H. pylori, and hepatocellular carcinoma from New Day Diagnostics, and licensed liver disease diagnostic assets from Cirna Diagnostics.
medical-diagnosticschronic-liver-diseaseeuropean-union-diagnostic-marketsceliac-disease-diagnosticsrespiratory-disease-diagnosticshepatocellular-carcinoma-diagnosticsce-mark-(european-conformity-for-medical-devices)
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/HEPA
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
Rencofilstat (CRV431)platformCyclophilin inhibitor previously developed for chronic liver disease treatment; assets sold to Panetta Partners Limited in May 2025.
Celiac Disease Diagnostic TesthardwareCE-marked diagnostic test licensed from New Day Diagnostics, eligible for sale in EU and CE-mark accepting markets.
Respiratory Multiplex Diagnostic TesthardwareCE-marked test for Covid/Influenza A/B and RSV, licensed from New Day Diagnostics for EU and eligible markets.
H. pylori Diagnostic TesthardwareCE-marked helicobacter pylori diagnostic test licensed from New Day Diagnostics for EU and eligible markets.
Hepatocellular Carcinoma (HCC) Diagnostic TesthardwareDiagnostic test for HCC licensed from New Day Diagnostics.
Liver Disease Diagnostic AssetsplatformIntellectual property and diagnostic assets licensed from Cirna Diagnostics, LLC for liver disease diagnosis.

Partnerships

PartnerTypeDescription
New Day Diagnostics LLClicensingIn-licensed diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC; paid $525,000 cash plus stock with up to $17.15M in milestones.
Panetta Partners LimitedlicensingSold all rencofilstat patent assets, knowhow, clinical data, and drug product; Panetta assumed contingent obligations and issued CVR to stockholders.
Cirna Diagnostics, LLClicensingLicensed certain liver disease diagnostic assets via intellectual property license agreement entered February 25, 2026.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/HEPA/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub